دورية أكاديمية
أعرض في EDS

Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas.

التفاصيل البيبلوغرافية
العنوان: Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas.
المؤلفون: Gauss C; Carman and Ann Adams Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI 48202, USA., Stone LD; Oral & Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Ghafouri M; Carman and Ann Adams Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI 48202, USA., Quan D; Department of Otolaryngology Head and Neck Surgery, School of Medicine, Wayne State University, Detroit, MI 48202, USA., Johnson J; Department of Otolaryngology Head and Neck Surgery, School of Medicine, Wayne State University, Detroit, MI 48202, USA., Fribley AM; Carman and Ann Adams Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI 48202, USA.; Department of Otolaryngology Head and Neck Surgery, School of Medicine, Wayne State University, Detroit, MI 48202, USA.; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48202, USA., Amm HM; Oral & Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
المصدر: Cells [Cells] 2024 Jun 11; Vol. 13 (12). Date of Electronic Publication: 2024 Jun 11.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Squamous Cell Carcinoma of Head and Neck*/therapy , Squamous Cell Carcinoma of Head and Neck*/pathology , Standard of Care* , Drug Resistance, Neoplasm* , Head and Neck Neoplasms*/therapy , Head and Neck Neoplasms*/pathology, Humans ; Signal Transduction ; DNA Repair ; Epigenesis, Genetic
مستخلص: Although there have been some advances during in recent decades, the treatment of head and neck squamous cell carcinoma (HNSCC) remains challenging. Resistance is a major issue for various treatments that are used, including both the conventional standards of care (radiotherapy and platinum-based chemotherapy) and the newer EGFR and checkpoint inhibitors. In fact, all the non-surgical treatments currently used for HNSCC are associated with intrinsic and/or acquired resistance. Herein, we explore the cellular mechanisms of resistance reported in HNSCC, including those related to epigenetic factors, DNA repair defects, and several signaling pathways. This article discusses these mechanisms and possible approaches that can be used to target different pathways to sensitize HNSCC to the existing treatments, obtain better responses to new agents, and ultimately improve the patient outcomes.
References: Lancet Oncol. 2019 Sep;20(9):1295-1305. (PMID: 31351869)
Biomolecules. 2019 Nov 17;9(11):. (PMID: 31744193)
Biomolecules. 2021 Oct 28;11(11):. (PMID: 34827592)
Front Oncol. 2021 Feb 25;11:614332. (PMID: 33718169)
Int J Mol Sci. 2022 Dec 06;23(23):. (PMID: 36499710)
Oncologist. 2009 Sep;14(9):900-8. (PMID: 19726454)
PLoS One. 2020 Feb 18;15(2):e0229077. (PMID: 32069320)
Oncol Lett. 2018 Oct;16(4):4799-4806. (PMID: 30250544)
Am J Cancer Res. 2016 Sep 01;6(9):1963-1975. (PMID: 27725902)
Oral Oncol. 2015 Apr;51(4):291-8. (PMID: 25532816)
Ann Transl Med. 2016 Dec;4(24):522. (PMID: 28149884)
Clin Transl Radiat Oncol. 2023 Jan 31;39:100590. (PMID: 36935854)
Lancet Oncol. 2021 Jun;22(6):883-892. (PMID: 33989559)
Oral Oncol. 2015 May;51(5):483-92. (PMID: 25754170)
Genes Dev. 2022 Mar 1;36(5-6):278-293. (PMID: 35318271)
Cancer Res. 2009 Apr 15;69(8):3415-24. (PMID: 19351843)
Cells. 2020 Nov 23;9(11):. (PMID: 33238461)
Cells. 2022 Feb 05;11(3):. (PMID: 35159370)
Oncologist. 2013;18(7):850-64. (PMID: 23821327)
Clin Cancer Res. 1999 Jun;5(6):1243-8. (PMID: 10389906)
Oral Oncol. 2012 Nov;48(11):1085-9. (PMID: 22840785)
Oral Oncol. 2015 Jan;51(1):53-8. (PMID: 25255959)
Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):846-53. (PMID: 12788194)
J Clin Oncol. 2007 Jun 1;25(16):2164-70. (PMID: 17538160)
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63. (PMID: 24355989)
Int J Mol Sci. 2020 Dec 29;22(1):. (PMID: 33383632)
Free Radic Biol Med. 2008 Jan 1;44(1):1-13. (PMID: 17967430)
Dent Clin North Am. 2018 Jan;62(1):29-46. (PMID: 29126492)
J Oral Microbiol. 2016 Sep 26;8:32762. (PMID: 27677454)
Carcinogenesis. 2019 Dec 31;40(12):1452-1461. (PMID: 31436806)
Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S106-8. (PMID: 17848273)
Proc Natl Acad Sci U S A. 1990 Dec;87(24):10028-32. (PMID: 2263603)
J Dent Res. 2018 Jun;97(6):635-644. (PMID: 29489434)
Cancers (Basel). 2022 Apr 05;14(7):. (PMID: 35406601)
Gastroenterology. 1994 Jan;106(1):42-8. (PMID: 8276207)
Mol Cancer Ther. 2019 Nov;18(11):1909-1915. (PMID: 31676542)
Cancers (Basel). 2021 Dec 02;13(23):. (PMID: 34885184)
Neoplasma. 2012;59(5):508-15. (PMID: 22668015)
Microbiol Spectr. 2022 Jun 29;10(3):e0068122. (PMID: 35608342)
J Exp Clin Cancer Res. 2019 Jun 10;38(1):245. (PMID: 31182137)
Front Oral Maxillofac Med. 2022 Sep;4:. (PMID: 36105623)
Clin Cancer Res. 2014 Jan 15;20(2):289-95. (PMID: 24270683)
Oncotarget. 2019 Jan 11;10(4):494-510. (PMID: 30728900)
Oncol Rep. 2009 Feb;21(2):507-13. (PMID: 19148529)
Cancers (Basel). 2022 Dec 10;14(24):. (PMID: 36551565)
Cell Death Dis. 2021 Jul 13;12(7):694. (PMID: 34257274)
Oncotarget. 2016 Mar 29;7(13):16731-44. (PMID: 26934442)
Int J Environ Res Public Health. 2020 Jul 23;17(15):. (PMID: 32718003)
Radiother Oncol. 2009 Sep;92(3):393-8. (PMID: 19616334)
Cancer Res. 2002 Dec 15;62(24):7350-6. (PMID: 12499279)
J Clin Oncol. 2010 Feb 10;28(5):761-6. (PMID: 20048189)
Cancers (Basel). 2021 Mar 23;13(6):. (PMID: 33806792)
Clin Cancer Res. 2012 Sep 15;18(18):4986-96. (PMID: 22825581)
Transl Cancer Res. 2013 Oct;2(5):412-421. (PMID: 24466508)
Front Mol Biosci. 2023 Aug 01;10:1148389. (PMID: 37602328)
Int J Mol Sci. 2023 Feb 03;24(3):. (PMID: 36769317)
OTO Open. 2019 Dec 10;3(4):2473974X19891126. (PMID: 31840132)
Anticancer Res. 2007 Sep-Oct;27(5A):3355-66. (PMID: 17970081)
Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11. (PMID: 16341240)
Semin Plast Surg. 2010 May;24(2):127-36. (PMID: 22550433)
Springerplus. 2016 Sep 21;5(1):1626. (PMID: 27722045)
Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41. (PMID: 24794262)
Drug Discov Today. 2021 Nov;26(11):2699-2706. (PMID: 34029690)
Br J Cancer. 2020 Dec;123(12):1720-1729. (PMID: 32963347)
J Clin Oncol. 2006 Sep 1;24(25):4170-6. (PMID: 16943533)
Int J Cancer. 2019 Oct 15;145(8):2100-2106. (PMID: 30468243)
J Dent Res. 2019 Sep;98(10):1073-1080. (PMID: 31340724)
Cancer. 2019 Sep 15;125(18):3208-3218. (PMID: 31246283)
Br J Cancer. 2008 Jul 8;99(1):167-72. (PMID: 18594541)
Clin Cancer Res. 1999 Oct;5(10):2884-90. (PMID: 10537357)
Expert Opin Drug Discov. 2021 Sep;16(9):977-989. (PMID: 33543671)
PLoS One. 2015 Feb 06;10(2):e0117781. (PMID: 25658924)
Oral Oncol. 2016 May;56:84-92. (PMID: 26733183)
Ann N Y Acad Sci. 2014 Dec;1333:1-32. (PMID: 25532687)
Ann Oncol. 2005 May;16(5):743-8. (PMID: 15802278)
Eur Arch Otorhinolaryngol. 2023 Nov;280(11):5049-5057. (PMID: 37535081)
Genes Dev. 2006 May 15;20(10):1331-42. (PMID: 16702406)
Clin Cancer Res. 1996 Nov;2(11):1859-65. (PMID: 9816141)
Oncotarget. 2016 Aug 9;7(32):51082-51095. (PMID: 27322774)
Cell Cycle. 2007 May 2;6(9):1006-10. (PMID: 17457049)
Am J Mens Health. 2021 May-Jun;15(3):15579883211016361. (PMID: 33993787)
Cell Death Differ. 2006 May;13(5):738-47. (PMID: 16485028)
Oral Oncol. 2009 Apr-May;45(4-5):324-34. (PMID: 18805044)
J Cancer Res Clin Oncol. 2022 Nov;148(11):2995-3005. (PMID: 34853888)
Front Oncol. 2021 Mar 05;11:596290. (PMID: 33747915)
Cancer Res. 2008 May 1;68(9):3421-8. (PMID: 18451170)
Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):45-57. (PMID: 21110823)
Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1277-81. (PMID: 18086972)
Front Oncol. 2021 Jun 11;11:678966. (PMID: 34178665)
Cell. 2015 Feb 26;160(5):963-976. (PMID: 25723170)
Cancers (Basel). 2023 Feb 12;15(4):. (PMID: 36831517)
Front Oncol. 2022 Aug 16;12:940377. (PMID: 36052247)
Oncology. 2007;73(1-2):104-11. (PMID: 18337622)
Epigenetics. 2015;10(6):545-61. (PMID: 25961636)
Cancer Res. 2000 Dec 15;60(24):6788-93. (PMID: 11156366)
Nat Rev Cancer. 2022 Nov;22(11):625-639. (PMID: 36064595)
J Mol Cell Biol. 2019 Jul 19;11(7):615-619. (PMID: 31283825)
Int J Biol Sci. 2021 Mar 10;17(4):1104-1118. (PMID: 33867833)
Front Oncol. 2021 Sep 10;11:697967. (PMID: 34568028)
Int J Mol Sci. 2022 Dec 12;23(24):. (PMID: 36555391)
J Oral Pathol Med. 2002 Sep;31(8):443-9. (PMID: 12220350)
Ann Surg. 1937 Oct;106(4):584-98. (PMID: 17857061)
Clin Cancer Res. 2015 Jun 15;21(12):2792-801. (PMID: 25724523)
Br J Cancer. 2022 Feb;126(3):361-370. (PMID: 34876674)
Antioxidants (Basel). 2023 Feb 04;12(2):. (PMID: 36829935)
Pharmacol Res. 2016 Apr;106:27-36. (PMID: 26804248)
Clin Cancer Res. 2020 Dec 1;26(23):6335-6349. (PMID: 32943458)
Cancer. 2020 Jul 15;126(14):3237-3243. (PMID: 32365226)
Int J Mol Sci. 2022 Dec 25;24(1):. (PMID: 36613780)
Eur J Cancer. 2019 Dec;123:36-47. (PMID: 31648099)
Med Res Rev. 2022 Jan;42(1):112-155. (PMID: 33928670)
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-14. (PMID: 35486888)
Int J Mol Sci. 2019 Aug 24;20(17):. (PMID: 31450627)
Oncogene. 2020 Apr;39(18):3638-3649. (PMID: 32157215)
Cancer Treat Rev. 2023 Feb;113:102492. (PMID: 36640618)
Biochem Biophys Res Commun. 2019 Sep 10;517(1):36-42. (PMID: 31311651)
Clin Cancer Res. 2001 Oct;7(10):2984-97. (PMID: 11595686)
Am J Cancer Res. 2020 Sep 01;10(9):2742-2751. (PMID: 33042614)
Br J Cancer. 2014 Jun 10;110(12):2887-95. (PMID: 24823695)
Clin Cancer Res. 2009 Jun 15;15(12):4174-80. (PMID: 19509163)
Cell Rep Med. 2022 Sep 20;3(9):100659. (PMID: 36130479)
J Pathol Inform. 2022 Nov 08;13:100153. (PMID: 36605112)
Oral Oncol. 2021 Jun;117:105292. (PMID: 33862558)
Int J Mol Sci. 2020 Sep 24;21(19):. (PMID: 32987799)
Lancet. 2019 Jan 12;393(10167):156-167. (PMID: 30509740)
Oral Oncol. 2019 Aug;95:35-42. (PMID: 31345392)
Semin Oncol. 2014 Apr;41(2):217-34. (PMID: 24787294)
FEBS Open Bio. 2013 Dec 30;4:96-104. (PMID: 24490130)
Expert Opin Investig Drugs. 2019 Apr;28(4):351-363. (PMID: 30753792)
Oral Oncol. 2017 Jun;69:38-45. (PMID: 28559019)
Oncol Lett. 2016 Dec;12(6):5315-5320. (PMID: 28105240)
Sci Transl Med. 2023 Aug 16;15(709):eabm3687. (PMID: 37585503)
Clin Cancer Res. 2017 Mar 15;23(6):1379-1387. (PMID: 28039268)
J Cell Biochem. 2016 Jun;117(6):1279-87. (PMID: 26774024)
J Clin Oncol. 2004 Nov 15;22(22):4632-42. (PMID: 15542813)
Clin Cancer Res. 2011 Aug 1;17(15):5197-204. (PMID: 21653686)
Cancer Res. 2003 Dec 1;63(23):8097-102. (PMID: 14678959)
Antioxidants (Basel). 2021 Feb 07;10(2):. (PMID: 33562328)
Pharmacol Rev. 2012 Jul;64(3):706-21. (PMID: 22659329)
Ann Oncol. 2017 Oct 1;28(10):2533-2538. (PMID: 28961834)
J Natl Cancer Inst. 1998 Jun 3;90(11):824-32. (PMID: 9625170)
Crit Rev Oncol Hematol. 2020 Apr;148:102885. (PMID: 32062315)
Oncogene. 2012 Jul 12;31(28):3322-32. (PMID: 22037217)
J Biomed Sci. 2013 Jun 27;20:43. (PMID: 23806066)
Neoplasia. 2007 Oct;9(10):801-11. (PMID: 17971900)
J Cell Mol Med. 2022 Dec;26(23):5807-5819. (PMID: 36308422)
Mol Cancer Ther. 2015 May;14(5):1141-51. (PMID: 25731184)
Clin Cancer Res. 2022 Mar 15;28(6):1203-1216. (PMID: 34980600)
Oral Oncol. 2019 Oct;97:82-91. (PMID: 31450171)
Mol Metab. 2021 Mar;45:101165. (PMID: 33453420)
Genes Chromosomes Cancer. 2014 Feb;53(2):129-43. (PMID: 24327542)
Int J Mol Sci. 2020 Dec 04;21(23):. (PMID: 33291532)
Clin Cancer Res. 2006 Sep 1;12(17):5064-73. (PMID: 16951222)
Br J Radiol. 2014 Apr;87(1036):20130677. (PMID: 24649835)
J Cell Biochem. 2016 Dec;117(12):2682-2692. (PMID: 27166782)
Clin Cancer Res. 2012 Apr 15;18(8):2278-89. (PMID: 22351687)
N Engl J Med. 2006 Feb 9;354(6):567-78. (PMID: 16467544)
Front Oncol. 2022 Jun 09;12:894744. (PMID: 35756670)
Biomolecules. 2020 Apr 25;10(5):. (PMID: 32344837)
Oncology. 2015;89(4):227-34. (PMID: 26066774)
J Microbiol Biotechnol. 2017 Aug 28;27(8):1367-1378. (PMID: 28621113)
Oral Oncol. 2011 Jun;47(6):487-96. (PMID: 21498106)
Am J Transl Res. 2009 Mar 08;1(3):249-58. (PMID: 19956435)
Cell Death Dis. 2022 Mar 25;13(3):267. (PMID: 35338115)
Sci Rep. 2021 Jul 20;11(1):14755. (PMID: 34285300)
J Natl Compr Canc Netw. 2022 Mar;20(3):224-234. (PMID: 35276673)
Eur J Pharmacol. 2017 Sep 5;810:70-82. (PMID: 28583430)
Int J Mol Sci. 2017 Jul 12;18(7):. (PMID: 28704968)
J Clin Oncol. 2020 Apr 10;38(11):1154-1163. (PMID: 31961766)
معلومات مُعتمدة: T90-DE022736 United States DE NIDCR NIH HHS
فهرسة مساهمة: Keywords: HNSCC; cetuximab; chemotherapy resistance; cisplatin; clinical trials; oral cancer
تواريخ الأحداث: Date Created: 20240626 Date Completed: 20240626 Latest Revision: 20240628
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC11201455
DOI: 10.3390/cells13121018
PMID: 38920648
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4409
DOI:10.3390/cells13121018